Scholarlink

Purpose <p>This review aimed to evaluate the diagnostic performance of Neck Imaging Reporting and Data System (NIRADS) categories using 2-deoxy 2-(Fluorine-18) fluoro D-glucose positron emission tomography integrated with computed tomography (F-18 FDG PET/CT) to diagnose recurrence or treatment failure in the post-treatment assessment of head and neck squamous cell carcinoma (HNSCC).</p> Methods <p>A systematic search of the indexed medical literature was conducted till 7 November 2024 using PubMed, Scopus, Cochrane Library and Google Scholar to include studies reporting post-treatment recurrence rates on F-18-FDG PET/CT as per the NIRADS criteria. Studies were qualitatively assessed for risk of bias using the QUADAS-2 tool. We categorized patients with ‘NI-RADS≤2’ as low risk of recurrence and ’NI-RADS ≥3’ as high risk of recurrence. Diagnostic performance of NI-RADS was evaluated through weighted-pooling of standard metrics of diagnostic accuracy, diagnostic Odd’s ratio (DOR) and summary receiver operator characteristic (SROC) curve analysis.</p> Results <p>Out of 1632 records identified, 8 studies with 7 datasets were included, with over 1200 patients and over 1300 F-18 FDG PET/CT scans. All studies were retrospective, with presence of a risk for bias, publication bias and data heterogeneity. The time between treatment and F-18 FDG PET/CT assessment was 8–17 weeks. For combined sites (primary, nodal or distant sites), the ability of ’NIRADS ≥3’ over ‘NIRADS ≤2’ to detect a recurrence was acceptable with a pooled sensitivity, specificity, positive and negative likelihood ratios of 0.68 (95% Confidence Interval, CI 0.63–0.73), 0.90 (95% CI, 0.88–0.92), 6.01 (95% CI, 2.9– 12.6) and 0.47 (95% CI, 0.31– 0.71) respectively, with a DOR of 14.13 (95% CI, 9.78–20.42) and an area under the curve, AUC of 0.859 (Standard Error, SE -0.018) on SROC analysis</p> Conclusion <p>In F-18 FDG PET/CT done on post-treatment HNSCC patients, the diagnostic performance of NIRADS ≥3 categories over NIRADS ≤ 2 categories in detecting treatment failure or recurrence at combined primary, nodal or distant sites was acceptable, with a low certainty of evidence. The NIRADS categories, especially NIRADS ≥3 and NIRADS ≤2 categories should be routinely reported in post-treatment F-18 FDG PET/CT scans in HNSCC patients. (No funding received; PROSPERO No. CRD42022376017)</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Diagnostic performance of NIRADS on F-18 FDG PET/CT in the post-treatment assessment of head and neck malignancies - a systematic review and meta-analysis

  • 期刊论文

  • 发表日期：

    2025年3月26日

查看全文
  • Deepanksha Datta,
  • B. Selvakumar,
  • Akhil Dhanesh Goel,
  • Sanskriti Chhibber,
  • Tejpal Gupta

摘要

Purpose

This review aimed to evaluate the diagnostic performance of Neck Imaging Reporting and Data System (NIRADS) categories using 2-deoxy 2-(Fluorine-18) fluoro D-glucose positron emission tomography integrated with computed tomography (F-18 FDG PET/CT) to diagnose recurrence or treatment failure in the post-treatment assessment of head and neck squamous cell carcinoma (HNSCC).

Methods

A systematic search of the indexed medical literature was conducted till 7 November 2024 using PubMed, Scopus, Cochrane Library and Google Scholar to include studies reporting post-treatment recurrence rates on F-18-FDG PET/CT as per the NIRADS criteria. Studies were qualitatively assessed for risk of bias using the QUADAS-2 tool. We categorized patients with ‘NI-RADS≤2’ as low risk of recurrence and ’NI-RADS ≥3’ as high risk of recurrence. Diagnostic performance of NI-RADS was evaluated through weighted-pooling of standard metrics of diagnostic accuracy, diagnostic Odd’s ratio (DOR) and summary receiver operator characteristic (SROC) curve analysis.

Results

Out of 1632 records identified, 8 studies with 7 datasets were included, with over 1200 patients and over 1300 F-18 FDG PET/CT scans. All studies were retrospective, with presence of a risk for bias, publication bias and data heterogeneity. The time between treatment and F-18 FDG PET/CT assessment was 8–17 weeks. For combined sites (primary, nodal or distant sites), the ability of ’NIRADS ≥3’ over ‘NIRADS ≤2’ to detect a recurrence was acceptable with a pooled sensitivity, specificity, positive and negative likelihood ratios of 0.68 (95% Confidence Interval, CI 0.63–0.73), 0.90 (95% CI, 0.88–0.92), 6.01 (95% CI, 2.9– 12.6) and 0.47 (95% CI, 0.31– 0.71) respectively, with a DOR of 14.13 (95% CI, 9.78–20.42) and an area under the curve, AUC of 0.859 (Standard Error, SE -0.018) on SROC analysis

Conclusion

In F-18 FDG PET/CT done on post-treatment HNSCC patients, the diagnostic performance of NIRADS ≥3 categories over NIRADS ≤ 2 categories in detecting treatment failure or recurrence at combined primary, nodal or distant sites was acceptable, with a low certainty of evidence. The NIRADS categories, especially NIRADS ≥3 and NIRADS ≤2 categories should be routinely reported in post-treatment F-18 FDG PET/CT scans in HNSCC patients. (No funding received; PROSPERO No. CRD42022376017)